期刊文献+

A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine 被引量:2

A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine
原文传递
导出
摘要 Background Developing an effective vaccine against human immunodeficiency virus type 1 (HIV-1) remains a grand challenge after more than two decades of intensive effort. It is partially due to the lack of suitable animal models for screening and prioritizing vaccine candidates. In this study, we aim to develop a mice model to test HIV-1 vaccine efficacy. Methods We constructed a recombinant vaccinia expressing firefly luciferase and HIV-1 Gag fusion protein based on Tiantan strain, an attenuated but replication-competent poxvirus (rTTV-lucgag). By quantifying the luciferase activity as its read out, we defined the biodistribution of Tiantan strain poxvirus in mice inoculated intraperitoneally and attempted to apply this model to evaluate the HIV-1 vaccine efficacy. Results Our data demonstrated that the rTTV-lucgag was able to express high level of luciferase (〈106 relative luciferase units (RLU)/mg protein) and HIV-1 Gag (〉3 folds increase comparing to the control). After intraperitoneal inoculation, this virus had dominant replication in the ovary, uterus, and cervix of mice and the luciferase activities in those organs are significantly correlated with viral titers (r^2=0.71, P 〈0.01). Pre-immunization with an HIV gag DNA vaccine reduced the luciferase activity in ovary from (6006±3141) RLU/mg protein in control group to (1538±463) RLU/mg protein in vaccine group (P=0.1969). Conclusions The luciferase activity in ovary could represent viral replication in vivo; this rTTV-lucgag/mice model may be suitable to assess the protective efficacy of cytotoxic T-cell responses to HIV Gag with less tedious work and high through-put. Background Developing an effective vaccine against human immunodeficiency virus type 1 (HIV-1) remains a grand challenge after more than two decades of intensive effort. It is partially due to the lack of suitable animal models for screening and prioritizing vaccine candidates. In this study, we aim to develop a mice model to test HIV-1 vaccine efficacy. Methods We constructed a recombinant vaccinia expressing firefly luciferase and HIV-1 Gag fusion protein based on Tiantan strain, an attenuated but replication-competent poxvirus (rTTV-lucgag). By quantifying the luciferase activity as its read out, we defined the biodistribution of Tiantan strain poxvirus in mice inoculated intraperitoneally and attempted to apply this model to evaluate the HIV-1 vaccine efficacy. Results Our data demonstrated that the rTTV-lucgag was able to express high level of luciferase (〈106 relative luciferase units (RLU)/mg protein) and HIV-1 Gag (〉3 folds increase comparing to the control). After intraperitoneal inoculation, this virus had dominant replication in the ovary, uterus, and cervix of mice and the luciferase activities in those organs are significantly correlated with viral titers (r^2=0.71, P 〈0.01). Pre-immunization with an HIV gag DNA vaccine reduced the luciferase activity in ovary from (6006±3141) RLU/mg protein in control group to (1538±463) RLU/mg protein in vaccine group (P=0.1969). Conclusions The luciferase activity in ovary could represent viral replication in vivo; this rTTV-lucgag/mice model may be suitable to assess the protective efficacy of cytotoxic T-cell responses to HIV Gag with less tedious work and high through-put.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2009年第14期1655-1659,共5页 中华医学杂志(英文版)
基金 This research was supported by the National Natural Science Foundation of China (No. 30771915), the National Grand Program on Key Infectious Disease (No. 2008ZX10001-02 Project 2 and 2008ZX10001-012) from the China Ministry of Health & Ministry of Sciences and Technology, China.
关键词 human immunodeficiency virus type 1 vaccine mice model LUCIFERASE human immunodeficiency virus type 1 vaccine mice model luciferase
  • 相关文献

参考文献20

  • 1Kumar A,Narayan O.Immunization for long-term protection against AIDS using the macaque model.Virology 2001; 285:1-5.
  • 2Locher CP,Witt SA,Herndier BG,Tenner-Racz K,Racz P,Levy JA.Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development.Immunol Rev 2001; 183:127-140.
  • 3Boberg A,Brave A,Johansson S,Wahren B,Hinkula J,Rollman E.Murine model for HIV vaccination and challenge.Expert Rev Vaccines 2008; 7:117-130.
  • 4Saxon A,Macy E,Denis K,Tary-Lehmann M,Witte O,BraunJ.Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans.J Clin Invest 1991; 87:658-665.
  • 5Mosier DE,Gulizia R J,Baird SM,Wilson DB.Transfer of a functional human immune system to mice with severe combined immunodeficiency.Nature 1988; 335:256-259.
  • 6Borkow G Mouse models for HIV-1 infection.IUBMB Life 2005; 57:819-823.
  • 7Garcia S,Dadaglio G,Gougeon ML.Limits of the human-PBL-SCID mice model:Severe restriction of the V beta T-cell repertoire of engrafted human T cells.Blood 1997;89:329-336.
  • 8Tary-Lehmann M,Saxon A.Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood.J Exp Med 1992; 175:503-516.
  • 9Belyakov IM,Derby MA,Ahlers JD,Kelsall BL,Earl P,Moss B,et al.Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.Proc Nail Acad Sci U S A 1998; 95:1709-1714.
  • 10Shinoda K,Xin KQ,Okuda K.A modified HIV challenge assay in mice by using luciferase-expressing vaccinia virus.Vaccine 2006; 24:2751-2754.

同被引文献2

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部